---
title: "《盈警》石四药集团营业额下降  料全年少赚 45%-60%"
description: "石四药集团发盈警，预计 2025 年度溢利将较上年度的 10.61 亿元下降 45%-60%。主要由于国内没有大规模流行病发生叠加医保控费导致药品终端销量下降、带量采购范围扩大以及国内外行业竞争加剧带来持续的价格压力以及盐酸溴己新安瓿注射液不再通过国家药品集采销售，导致营业额下降。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/276340734.md"
published_at: "2026-02-19T13:48:52.000Z"
---

# 《盈警》石四药集团营业额下降  料全年少赚 45%-60%

> 石四药集团发盈警，预计 2025 年度溢利将较上年度的 10.61 亿元下降 45%-60%。主要由于国内没有大规模流行病发生叠加医保控费导致药品终端销量下降、带量采购范围扩大以及国内外行业竞争加剧带来持续的价格压力以及盐酸溴己新安瓿注射液不再通过国家药品集采销售，导致营业额下降。

石四药集团 (02005.HK) 发盈警，预计 2025 年度溢利将较上年度的 10.61 亿元下降 45%-60%。主要由於国内没有大规模流行病发生叠加医保控费导致药品终端销量下降、带量采购范围扩大以及国内外行业竞争加剧带来持续的价格压力以及盐酸溴己新安瓿注射液不再通过国家药品集采销售，导致营业额下降。

### Related Stocks

- [01093.HK - 石药集团](https://longbridge.com/zh-CN/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-CN/news/276035104.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/zh-CN/news/275991027.md) |
| Fair drug pricing requires legislation, not executive orders | The article argues that fair drug pricing requires legislation rather than executive orders, highlighting the limitation | [Link](https://longbridge.com/zh-CN/news/276261541.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-CN/news/276113491.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。